Motor assessment in Parkinson`s disease

Opara, Józef; Małecki, Andrzej; Małecka, Elżbieta; Socha, Teresa

doi:10.5604/12321966.1232774

Cited by 194 publications

(128 citation statements)

References 9 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…17β‐HSD10 has the ability to promote neurodegenerative processes and apoptosis of neurons thereby playing an important role in neurodegenerative disorders (Oppermann et al., 1999; Yan et al., 1999). A role for 17β‐HSD10 is confirmed in Parkinson's disease (PD) (Tieu et al., 2004), which is a neurodegenerative disease manifested by the reduction in dopaminergic neurons in the substantia nigra resulting in motor symptoms as shaking, rigidity and postural instability, and walking problems (Opara, Małecki, Małecka, & Socha, 2017). Patients with PD have significantly down‐regulated the expression of 17β‐HSD10, resulting in reduced levels of the enzyme in dopaminergic neurons.…”

Section: β‐Hsd10‐related Diseasesmentioning

confidence: 99%

Friend or enemy? Review of 17β‐HSD10 and its role in human health or disease

Vinklářová

Schmidt

Benek

et al. 2020

Journal of Neurochemistry

View full text Add to dashboard Cite

17β-HSD10 is a mitochondrial enzyme involved in the metabolism of a wide range of substrates, including neurosteroids (He, Dobkin, & Yang, 2019) and sex steroids, maintaining their physiological level (Shafqat et al., 2003). However, it also plays an important role in tRNA processing as a structural component of RNase P (Holzmann et al., 2008). Its abnormal function including inherited mutations leads to disruption in mitochondrial physiology and is thought to be one of the underlying pathological causes for diseases such as Alzheimer's disease (He, Isaacs, & Yang, 2018) and some forms of cancer (Yang, He, & Schulz, 2005). This paper discusses the role of 17β-HSD10 in physiology, as well as its connections to various diseases. The first section gives an overview of 17β-HSD10 structure, localization and physiological functions. In the second section, the role of 17β-HSD10 in disease, specifically in neurodegenerative disorders and cancer are discussed, which together are attracting more and broader interest in this enzyme.

show abstract

Section: β‐Hsd10‐related Diseasesmentioning

confidence: 99%

Friend or enemy? Review of 17β‐HSD10 and its role in human health or disease

Vinklářová

Schmidt

Benek

et al. 2020

Journal of Neurochemistry

View full text Add to dashboard Cite

show abstract

“…Postural instability during level-ground walking, obstacle crossing, and ascending and descending stairs is widely described in the literature (6,7,(17)(18)(19)(20)(21). There is evidence that people with PD present impaired postural control during gait with an additional task (17,22,23); therefore, a complex motor activity from daily life, such as crossing an obstacle or negotiating stairs, may be hazardous for people with PD.…”

Section: Introductionmentioning

confidence: 99%

Transitional Locomotor Tasks in People With Mild to Moderate Parkinson's Disease

Kamieniarz¹,

Michalska²,

Marszałek³

et al. 2020

Front. Neurol.

View full text Add to dashboard Cite

Background: People with Parkinson's disease (PD) exhibit deficits in maintaining balance both during quiet standing and during walking, turning, standing up from sitting, and step initiation. Objective: The purpose of this study was to examine balance disorders during a transitional task under different conditions in participants with PD. Methods: The research was conducted on 15 PD-II (mild) and 15 PD-III (moderate) individuals (H&Y II-III stage) and 30 healthy elderly. The transitional task was measured on two force platforms (A and B). The procedure consisted of three phases: (1) quiet standing on platform A, (2) crossing to platform B, and (3) quiet standing on platform B, each until measurements were completed. There were four conditions: crossing without an obstacle, crossing with an obstacle, and walking up and down the step. Results: There were no significant differences between mild PD individuals and healthy elderly during quiet standing before the transitional task and after completing the task. The temporal aspects describing the different transitional tasks were comparable between mild PD and healthy subjects. Moderate PD participants presented a significantly higher COP velocity after the transitional task compared to the healthy older adults (p < 0.05). Additionally, the moderate PD group showed significantly higher values for transit time relative to healthy subjects during the transitional task in all conditions (p < 0.05). Conclusions: Disease severity affects the temporal aspects of different transitional tasks in people with PD. The procedure of completing a transitional task under different conditions allowed differences between moderate and mild PD stages and healthy subjects to be observed.

show abstract

“…1 In addition to mental symptoms, patients with PD display typical motor symptoms such as postural instability, muscle rigidity, static tremors and difficulty with walking and gait. 2 PD is a complex multifactor disease characterized by the extensive presence of α-synuclein-containing Lewy bodies in the substantia nigra (SN), in the pars compacta of which loss of dopaminergic neurons leads to reduced facilitation of voluntary movements. 3 Literature in the past decade has suggested that genetic factors might play an important role in the development of PD.…”

Section: Introductionmentioning

confidence: 99%

<p>Lack of Association Between <em>PLA2G6</em> Genetic Variation and Parkinson’s Disease: A Systematic Review</p>

Yao

Liu

et al. 2020

NDT

View full text Add to dashboard Cite

Background: The phospholipase A2 Group 6 (PLA2G6, also known as PLA2, PARK14, and iPLA2) gene encodes a group VIA calcium-independent phospholipase A2. Genetic polymorphism of PLA2G6 has been indicated to be involved in conferring susceptibility for Parkinson's disease (PD), whereas conclusive results have not been obtained. Thus, we intended to conduct a systematic review to determine if PLA2G6 genetic variation confers a greater susceptibility to PD. Methods: All case-control studies that investigated the association of the PLA2G6 polymorphisms with the risk of PD published before 15 July 2018 were included. The literature was comprehensively searched and identified in five English databases (EBSCO, Pubmed, OVID, EMBASE and ISI Web of Knowledge) and four Chinese databases (Wanfang database, Chinese Biomedical Literature Database, China Academic Journals Database and VIP database). We performed analyses of study characteristics, heterogeneity, and forest plot in analyses analogous to dominant, codominant and additive models with the pooled odds ratio (OR) in fixedor random-effects models as the measure of association. Results: A total of 664 potentially relevant studies were retrieved with the initial search, of which eight studies fulfilled the inclusion criteria, and included 2,779 PD patients and 3,291 control participants,. Among all the reported 27 genetic variants, 15 single nucleotide polymorphisms (SNPs) were present only in patients, and only five available SNPs (rs2267369, rs140758033, c.1959T>A (Gly653Gly), rs76718524, rs199935023) were pooled in the meta-analysis. However, there was no evidence for a significant association between the five SNPs and PD risk in dominant, codominant and allele models, suggesting a lack of association between PLA2G6 genetic variation and PD susceptibility. Conclusion: The present study assessed the association of PLA2G6 genetic polymorphism with the risk PD, and the result strongly demonstrates that PLA2G6 polymorphism is not associated with PD susceptibility.

show abstract

Motor assessment in Parkinson`s disease

Cited by 194 publications

References 9 publications

Friend or enemy? Review of 17β‐HSD10 and its role in human health or disease

Friend or enemy? Review of 17β‐HSD10 and its role in human health or disease

Transitional Locomotor Tasks in People With Mild to Moderate Parkinson's Disease

<p>Lack of Association Between <em>PLA2G6</em> Genetic Variation and Parkinson’s Disease: A Systematic Review</p>

Contact Info

Product

Resources

About